Kime C, Mandegar MA, Srivastava D, Yamanaka S, Conklin BR, Rand TA.  2016.  Efficient CRISPR/Cas9-Based Genome Engineering in Human Pluripotent Stem Cells.. Curr Protoc Hum Genet. 88:Unit21.4.
Kime C, Rand TA, Ivey KN, Srivastava D, Yamanaka S, Tomoda K.  2015.  Practical Integration-Free Episomal Methods for Generating Human Induced Pluripotent Stem Cells.. Curr Protoc Hum Genet. 87:21.2.1-21.
Miki K, Endo K, Takahashi S, Funakoshi S, Takei I, Katayama S, Toyoda T, Kotaka M, Takaki T, Umeda M et al..  2015.  Efficient Detection and Purification of Cell Populations Using Synthetic MicroRNA Switches.. Cell Stem Cell. 16(6):699-711.
Li HLisa, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H et al..  2015.  Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.. Stem Cell Reports. 4(1):143-54.
Kim S-I, Oceguera-Yanez F, Hirohata R, Linker S, Okita K, Yamada Y, Yamamoto T, Yamanaka S, Woltjen K.  2015.  KLF4 N-terminal variance modulates induced reprogramming to pluripotency.. Stem Cell Reports. 4(4):727-43.
Hayashi Y, Caboni L, Das D, Yumoto F, Clayton T, Deller MC, Nguyen P, Farr CL, Chiu H-J, Miller MD et al..  2015.  Structure-based discovery of NANOG variant with enhanced properties to promote self-renewal and reprogramming of pluripotent stem cells.. Proc Natl Acad Sci U S A. 112(15):4666-71.
Sadahiro T, Yamanaka S, Ieda M.  2015.  Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications.. Circ Res. 116(8):1378-91.
Wilmut I, Leslie S, Martin NG, Peschanski M, Rao M, Trounson A, Turner D, Turner ML, Yamanaka S, Taylor CJ.  2015.  Development of a global network of induced pluripotent stem cell haplobanks.. Regen Med. 10(3):235-8.
Karagiannis P, Yamanaka S.  2014.  The fate of cell reprogramming.. Nat Methods. 11(10):1006-8.
Andrews PW, Cavanagro J, Deans R, Feigel E, Horowitz E, Keating A, Rao M, Turner M, Wilmut I, Yamanaka S.  2014.  Corrigendum: Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.. Nat Biotechnol. 32(11):1166.
Numasawa-Kuroiwa Y, Okada Y, Shibata S, Kishi N, Akamatsu W, Shoji M, Nakanishi A, Oyama M, Osaka H, Inoue K et al..  2014.  Involvement of ER stress in dysmyelination of Pelizaeus-Merzbacher Disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes.. Stem Cell Reports. 2(5):648-61.
Bershteyn M, Hayashi Y, Desachy G, Hsiao EC, Sami S, Tsang KM, Weiss LA, Kriegstein AR, Yamanaka S, Wynshaw-Boris A.  2014.  Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells.. Nature. 507(7490):99-103.
Hirata N, Nakagawa M, Fujibayashi Y, Yamauchi K, Murata A, Minami I, Tomioka M, Kondo T, Kuo T-F, Endo H et al..  2014.  A chemical probe that labels human pluripotent stem cells.. Cell Rep. 6(6):1165-74.
Worringer KA, Rand TA, Hayashi Y, Sami S, Takahashi K, Tanabe K, Narita M, Srivastava D, Yamanaka S.  2014.  The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes.. Cell Stem Cell. 14(1):40-52.
Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A, Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T et al..  2014.  Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.. Cell. 156(4):663-77.
Ohnuki M, Tanabe K, Sutou K, Teramoto I, Sawamura Y, Narita M, Nakamura M, Tokunaga Y, Nakamura M, Watanabe A et al..  2014.  Dynamic regulation of human endogenous retroviruses mediates factor-induced reprogramming and differentiation potential.. Proc Natl Acad Sci U S A. 111(34):12426-31.
C Spencer I, Baba S, Nakamura K, Hua EA, Sears MAF, Fu C-cheng, Zhang J, Balijepalli S, Tomoda K, Hayashi Y et al..  2014.  Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia.. Stem Cell Reports. 3(2):269-81.
Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H et al..  2014.  Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice.. Stem Cell Reports. 3(2):242-9.
Andrews PW, Cavagnaro J, Cavanagro J, Deans R, Feigal E, Feigel E, Horowitz E, Keating A, Rao M, Turner M et al..  2014.  Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.. Nat Biotechnol. 32(8):724-6.
Nakamura S, Takayama N, Hirata S, Seo H, Endo H, Ochi K, Fujita K-ichi, Koike T, Harimoto K-ichi, Dohda T et al..  2014.  Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells.. Cell Stem Cell. 14(4):535-48.
Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, Morizane A, Doi D, Takahashi J, Nishizawa M et al..  2014.  A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells.. Sci Rep. 4:3594.
Shimamoto R, Amano N, Ichisaka T, Watanabe A, Yamanaka S, Okita K.  2014.  Generation and characterization of induced pluripotent stem cells from Aid-deficient mice.. PLoS One. 9(4):e94735.
Tokunaga K, Saitoh N, Goldberg IG, Sakamoto C, Yasuda Y, Yoshida Y, Yamanaka S, Nakao M.  2014.  Computational image analysis of colony and nuclear morphology to evaluate human induced pluripotent stem cells.. Sci Rep. 4:6996.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Sasaki A, Yamamoto M, Nakamura M, Sutou K, Osafune K, Yamanaka S.  2014.  Induction of pluripotency in human somatic cells via a transient state resembling primitive streak-like mesendoderm.. Nat Commun. 5:3678.
Tamaoki N, Takahashi K, Aoki H, Iida K, Kawaguchi T, Hatakeyama D, Inden M, Chosa N, Ishisaki A, Kunisada T et al..  2014.  The homeobox gene DLX4 promotes generation of human induced pluripotent stem cells.. Sci Rep. 4:7283.
Tanabe K, Takahashi K, Yamanaka S.  2014.  Induction of pluripotency by defined factors.. Proc Jpn Acad Ser B Phys Biol Sci. 90(3):83-96.
Pandey RRaman, Tokuzawa Y, Yang Z, Hayashi E, Ichisaka T, Kajita S, Asano Y, Kunieda T, Sachidanandam R, Chuma S et al..  2013.  Tudor domain containing 12 (TDRD12) is essential for secondary PIWI interacting RNA biogenesis in mice.. Proc Natl Acad Sci U S A. 110(41):16492-7.
Turner M, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, Trounson A, Turner D, Yamanaka S, Wilmut I.  2013.  Toward the development of a global induced pluripotent stem cell library.. Cell Stem Cell. 13(4):382-4.
Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, Goshima N, Yamanaka S.  2013.  An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells.. Stem Cells. 31(3):458-66.
Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I et al..  2013.  Response to comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells".. Sci Transl Med. 5(188):188lr2.
Takahashi K, Yamanaka S.  2013.  Induced pluripotent stem cells in medicine and biology.. Development. 140(12):2457-61.
Veraitch O, Kobayashi T, Imaizumi Y, Akamatsu W, Sasaki T, Yamanaka S, Amagai M, Okano H, Ohyama M.  2013.  Human induced pluripotent stem cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vivo.. J Invest Dermatol. 133(6):1479-88.
Tanabe K, Nakamura M, Narita M, Takahashi K, Yamanaka S.  2013.  Maturation, not initiation, is the major roadblock during reprogramming toward pluripotency from human fibroblasts.. Proc Natl Acad Sci U S A. 110(30):12172-9.
Watanabe A, Yamada Y, Yamanaka S.  2013.  Epigenetic regulation in pluripotent stem cells: a key to breaking the epigenetic barrier.. Philos Trans R Soc Lond B Biol Sci. 368(1609):20120292.
Yamana R, Iwasaki M, Wakabayashi M, Nakagawa M, Yamanaka S, Ishihama Y.  2013.  Rapid and deep profiling of human induced pluripotent stem cell proteome by one-shot NanoLC-MS/MS analysis with meter-scale monolithic silica columns.. J Proteome Res. 12(1):214-21.
Yamanaka S.  2013.  Shinya Yamanaka: purveyor of pluripotency. Interview by Ruth Williams.. Circ Res. 112(2):233-5.
Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, Ikeda E, Yamanaka S, Miura K.  2013.  Steps toward safe cell therapy using induced pluripotent stem cells.. Circ Res. 112(3):523-33.
Fujishiro S-hei, Nakano K, Mizukami Y, Azami T, Arai Y, Matsunari H, Ishino R, Nishimura T, Watanabe M, Abe T et al..  2013.  Generation of naive-like porcine-induced pluripotent stem cells capable of contributing to embryonic and fetal development.. Stem Cells Dev. 22(3):473-82.
Payer B, Rosenberg M, Yamaji M, Yabuta Y, Koyanagi-Aoi M, Hayashi K, Yamanaka S, Saitou M, Lee JT.  2013.  Tsix RNA and the germline factor, PRDM14, link X reactivation and stem cell reprogramming.. Mol Cell. 52(6):805-18.
Yamanaka S.  2013.  The winding road to pluripotency (Nobel Lecture).. Angew Chem Int Ed Engl. 52(52):13900-9.
Koyanagi-Aoi M, Ohnuki M, Takahashi K, Okita K, Noma H, Sawamura Y, Teramoto I, Narita M, Sato Y, Ichisaka T et al..  2013.  Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells.. Proc Natl Acad Sci U S A. 110(51):20569-74.
Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K et al..  2013.  Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.. Cell Stem Cell. 12(4):487-96.
Kaneko S, Yamanaka S.  2013.  To be immunogenic, or not to be: that's the iPSC question.. Cell Stem Cell. 12(4):385-6.
Matsumoto Y, Hayashi Y, Schlieve CR, Ikeya M, Kim H, Nguyen TD, Sami S, Baba S, Barruet E, Nasu A et al..  2013.  Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation.. Orphanet J Rare Dis. 8:190.
Kamakura T, Makiyama T, Sasaki K, Yoshida Y, Wuriyanghai Y, Chen J, Hattori T, Ohno S, Kita T, Horie M et al..  2013.  Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture.. Circ J. 77(5):1307-14.
Mae S-I, Shono A, Shiota F, Yasuno T, Kajiwara M, Gotoda-Nishimura N, Arai S, Sato-Otubo A, Toyoda T, Takahashi K et al..  2013.  Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells.. Nat Commun. 4:1367.
Yamashita A, Liu S, Woltjen K, Thomas B, Meng G, Hotta A, Takahashi K, Ellis J, Yamanaka S, Rancourt DE.  2013.  Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells.. Sci Rep. 3:1978.
Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, Hayashi T, Onoe H, Shiina T, Yamanaka S et al..  2013.  Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate.. Stem Cell Reports. 1(4):283-92.
Miki K, Uenaka H, Saito A, Miyagawa S, Sakaguchi T, Higuchi T, Shimizu T, Okano T, Yamanaka S, Sawa Y.  2012.  Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats.. Stem Cells Transl Med. 1(5):430-7.
Lahti AL, Kujala VJ, Chapman H, Koivisto A-P, Pekkanen-Mattila M, Kerkelä E, Hyttinen J, Kontula K, Swan H, Conklin BR et al..  2012.  Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.. Dis Model Mech. 5(2):220-30.
Yamanaka S.  2012.  Induced pluripotent stem cells: past, present, and future.. Cell Stem Cell. 10(6):678-84.
Hayashi Y, Saitou M, Yamanaka S.  2012.  Germline development from human pluripotent stem cells toward disease modeling of infertility.. Fertil Steril. 97(6):1250-9.
Kajiwara M, Aoi T, Okita K, Takahashi R, Inoue H, Takayama N, Endo H, Eto K, Toguchida J, Uemoto S et al..  2012.  Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells.. Proc Natl Acad Sci U S A. 109(31):12538-43.
Tomoda K, Takahashi K, Leung K, Okada A, Narita M, N Yamada A, Eilertson KE, Tsang P, Baba S, White MP et al..  2012.  Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells.. Cell Stem Cell. 11(1):91-9.
Blanpain C, Daley GQ, Hochedlinger K, Passegué E, Rossant J, Yamanaka S.  2012.  Stem cells assessed.. Nat Rev Mol Cell Biol. 13(7):471-6.
Tanaka T, Takahashi K, Yamane M, Tomida S, Nakamura S, Oshima K, Niwa A, Nishikomori R, Kambe N, Hara H et al..  2012.  Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery.. Blood. 120(6):1299-308.
Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I et al..  2012.  Drug screening for ALS using patient-specific induced pluripotent stem cells.. Sci Transl Med. 4(145):145ra104.
Kobayashi Y, Okada Y, Itakura G, Iwai H, Nishimura S, Yasuda A, Nori S, Hikishima K, Konomi T, Fujiyoshi K et al..  2012.  Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity.. PLoS One. 7(12):e52787.
Okita K, Nagata N, Yamanaka S.  2011.  Immunogenicity of induced pluripotent stem cells.. Circ Res. 109(7):720-1.
Nori S, Okada Y, Yasuda A, Tsuji O, Takahashi Y, Kobayashi Y, Fujiyoshi K, Koike M, Uchiyama Y, Ikeda E et al..  2011.  Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice.. Proc Natl Acad Sci U S A. 108(40):16825-30.
Nakamura T, Nakagawa M, Ichisaka T, Shiota A, Yamanaka S.  2011.  Essential roles of ECAT15-2/Dppa2 in functional lung development.. Mol Cell Biol. 31(21):4366-78.
Wang Y-C, Nakagawa M, Garitaonandia I, Slavin I, Altun G, Lacharite RM, Nazor KL, Tran HT, Lynch CL, Leonardo TR et al..  2011.  Specific lectin biomarkers for isolation of human pluripotent stem cells identified through array-based glycomic analysis.. Cell Res. 21(11):1551-63.
Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K-I et al..  2011.  A more efficient method to generate integration-free human iPS cells.. Nat Methods. 8(5):409-12.
Maekawa M, Yamaguchi K, Nakamura T, Shibukawa R, Kodanaka I, Ichisaka T, Kawamura Y, Mochizuki H, Goshima N, Yamanaka S.  2011.  Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1.. Nature. 474(7350):225-9.
Higashi H, Brüstle O, Daley GQ, Yamanaka S.  2011.  The nomenclature system should be sustainable, but also practical.. Cell Stem Cell. 8(6):606-7.
Yoshida Y, Yamanaka S.  2011.  iPS cells: a source of cardiac regeneration.. J Mol Cell Cardiol. 50(2):327-32.
Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N.  2011.  Modeling familial Alzheimer's disease with induced pluripotent stem cells.. Hum Mol Genet. 20(23):4530-9.
Sakurai H, Yamanaka S.  2011.  [Research for cell therapy by induced pluripotent stem cell].. Nihon Rinsho. 69(12):2114-8.
Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S et al..  2011.  Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage.. Nat Biotechnol. 29(12):1132-44.
Okita K, Yamanaka S.  2011.  Induced pluripotent stem cells: opportunities and challenges.. Philos Trans R Soc Lond B Biol Sci. 366(1575):2198-207.
Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohyama M, Amagai M, Matsuzaki Y, Yamanaka S, Okano H et al..  2011.  Generation of human melanocytes from induced pluripotent stem cells.. PLoS One. 6(1):e16182.
Uosaki H, Fukushima H, Takeuchi A, Matsuoka S, Nakatsuji N, Yamanaka S, Yamashita JK.  2011.  Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression.. PLoS One. 6(8):e23657.
Fujiwara M, Yan P, Otsuji TG, Narazaki G, Uosaki H, Fukushima H, Kuwahara K, Harada M, Matsuda H, Matsuoka S et al..  2011.  Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A.. PLoS One. 6(2):e16734.
Yahata N, Asai M, Kitaoka S, Takahashi K, Asaka I, Hioki H, Kaneko T, Maruyama K, Saido TC, Nakahata T et al..  2011.  Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease.. PLoS One. 6(9):e25788.
Hiratsuka M, Uno N, Ueda K, Kurosaki H, Imaoka N, Kazuki K, Ueno E, Akakura Y, Katoh M, Osaki M et al..  2011.  Integration-free iPS cells engineered using human artificial chromosome vectors.. PLoS One. 6(10):e25961.
Iwabuchi KA, Yamakawa T, Sato Y, Ichisaka T, Takahashi K, Okita K, Yamanaka S.  2011.  ECAT11/L1td1 is enriched in ESCs and rapidly activated during iPSC generation, but it is dispensable for the maintenance and induction of pluripotency.. PLoS One. 6(5):e20461.
Espejel S, Roll GR, K McLaughlin J, Lee AY, Zhang JY, Laird DJ, Okita K, Yamanaka S, Willenbring H.  2010.  Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice.. J Clin Invest. 120(9):3120-6.
Imamura M, Aoi T, Tokumasu A, Mise N, Abe K, Yamanaka S, Noce T.  2010.  Induction of primordial germ cells from mouse induced pluripotent stem cells derived from adult hepatocytes.. Mol Reprod Dev. 77(9):802-11.
Homma K, Sone M, Taura D, Yamahara K, Suzuki Y, Takahashi K, Sonoyama T, Inuzuka M, Fukunaga Y, Tamura N et al..  2010.  Sirt1 plays an important role in mediating greater functionality of human ES/iPS-derived vascular endothelial cells.. Atherosclerosis. 212(1):42-7.
Okita K, Yamanaka S.  2010.  Induction of pluripotency by defined factors.. Exp Cell Res. 316(16):2565-70.
Kaichi S, Hasegawa K, Takaya T, Yokoo N, Mima T, Kawamura T, Morimoto T, Ono K, Baba S, Doi H et al..  2010.  Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice.. Cardiovasc Res. 88(2):314-23.
Nakahata T, Awaya T, Chang H, Mizuno Y, Niwa A, Fukada S-ichiro, Takeda S'ichi, Yamanaka S, Heike T.  2010.  Derivation of engraftable myogenic precursors from murine ES/iPS cells and generation of disease-specific iPS cells from patients with Duchenne muscular dystrophy (DMD) and other diseases.. Rinsho Shinkeigaku. 50(11):889.
Okita K, Hong H, Takahashi K, Yamanaka S.  2010.  Generation of mouse-induced pluripotent stem cells with plasmid vectors.. Nat Protoc. 5(3):418-28.
Yamanaka S, Blau HM.  2010.  Nuclear reprogramming to a pluripotent state by three approaches.. Nature. 465(7299):704-12.
Sato S, Yagi S, Arai Y, Hirabayashi K, Hattori N, Iwatani M, Okita K, Ohgane J, Tanaka S, Wakayama T et al..  2010.  Genome-wide DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) residing in mouse pluripotent stem cells.. Genes Cells. 15(6):607-18.
Yamanaka S.  2010.  An interview with... Shinya Yamanaka. Interview by Mary Muers.. Nat Rev Genet. 11(6):390.
Yamanaka S.  2010.  Patient-specific pluripotent stem cells become even more accessible.. Cell Stem Cell. 7(1):1-2.
Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S et al..  2010.  Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury.. Proc Natl Acad Sci U S A. 107(28):12704-9.
Mizuno Y, Chang H, Umeda K, Niwa A, Iwasa T, Awaya T, Fukada S-ichiro, Yamamoto H, Yamanaka S, Nakahata T et al..  2010.  Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells.. FASEB J. 24(7):2245-53.
Saunders LR, Sharma ADeep, Tawney J, Nakagawa M, Okita K, Yamanaka S, Willenbring H, Verdin E.  2010.  miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues.. Aging (Albany NY). 2(7):415-31.
Kazuki Y, Hiratsuka M, Takiguchi M, Osaki M, Kajitani N, Hoshiya H, Hiramatsu K, Yoshino T, Kazuki K, Ishihara C et al..  2010.  Complete genetic correction of ips cells from Duchenne muscular dystrophy.. Mol Ther. 18(2):386-93.
Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, Endo H, Yamaguchi T, Otsu M, Nishimura K, Nakanishi M et al..  2010.  Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells.. J Exp Med. 207(13):2817-30.
Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S.  2010.  Promotion of direct reprogramming by transformation-deficient Myc.. Proc Natl Acad Sci U S A. 107(32):14152-7.
Nakagawa M, Yamanaka S.  2010.  Reprogramming of somatic cells to pluripotency.. Adv Exp Med Biol. 695:215-24.
Egusa H, Okita K, Kayashima H, Yu G, Fukuyasu S, Saeki M, Matsumoto T, Yamanaka S, Yatani H.  2010.  Gingival fibroblasts as a promising source of induced pluripotent stem cells.. PLoS One. 5(9):e12743.
Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S.  2009.  Hypoxia enhances the generation of induced pluripotent stem cells.. Cell Stem Cell. 5(3):237-41.
Yokoo N, Baba S, Kaichi S, Niwa A, Mima T, Doi H, Yamanaka S, Nakahata T, Heike T.  2009.  The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells.. Biochem Biophys Res Commun. 387(3):482-8.
Nishimura K, Nakagawa T, Ono K, Ogita H, Sakamoto T, Yamamoto N, Okita K, Yamanaka S, Ito J.  2009.  Transplantation of mouse induced pluripotent stem cells into the cochlea.. Neuroreport. 20(14):1250-4.
Yamanaka S.  2009.  Ekiden to iPS Cells.. Nat Med. 15(10):1145-8.
Niwa A, Umeda K, Chang H, Saito M, Okita K, Takahashi K, Nakagawa M, Yamanaka S, Nakahata T, Heike T.  2009.  Orderly hematopoietic development of induced pluripotent stem cells via Flk-1(+) hemoangiogenic progenitors.. J Cell Physiol. 221(2):367-77.
Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K, Okita K, Yamanaka S, Nishimura Y.  2009.  Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells.. Stem Cells. 27(5):1021-31.
Daley GQ, M Lensch W, Jaenisch R, Meissner A, Plath K, Yamanaka S.  2009.  Broader implications of defining standards for the pluripotency of iPSCs.. Cell Stem Cell. 4(3):200-1;authorreply202.
Taura D, Noguchi M, Sone M, Hosoda K, Mori E, Okada Y, Takahashi K, Homma K, Oyamada N, Inuzuka M et al..  2009.  Adipogenic differentiation of human induced pluripotent stem cells: comparison with that of human embryonic stem cells.. FEBS Lett. 583(6):1029-33.
Tsubooka N, Ichisaka T, Okita K, Takahashi K, Nakagawa M, Yamanaka S.  2009.  Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts.. Genes Cells. 14(6):683-94.
Ohnuki M, Takahashi K, Yamanaka S.  2009.  Generation and characterization of human induced pluripotent stem cells.. Curr Protoc Stem Cell Biol. Chapter 4:Unit4A.2.
Hirami Y, Osakada F, Takahashi K, Okita K, Yamanaka S, Ikeda H, Yoshimura N, Takahashi M.  2009.  Generation of retinal cells from mouse and human induced pluripotent stem cells.. Neurosci Lett. 458(3):126-31.
Yamanaka S.  2009.  Elite and stochastic models for induced pluripotent stem cell generation.. Nature. 460(7251):49-52.
Taura D, Sone M, Homma K, Oyamada N, Takahashi K, Tamura N, Yamanaka S, Nakao K.  2009.  Induction and isolation of vascular cells from human induced pluripotent stem cells--brief report.. Arterioscler Thromb Vasc Biol. 29(7):1100-3.
Aiba K, Nedorezov T, Piao Y, Nishiyama A, Matoba R, Sharova LV, Sharov AA, Yamanaka S, Niwa H, Ko MSH.  2009.  Defining developmental potency and cell lineage trajectories by expression profiling of differentiating mouse embryonic stem cells.. DNA Res. 16(1):73-80.
Belmonte JCarlos Izp, Ellis J, Hochedlinger K, Yamanaka S.  2009.  Induced pluripotent stem cells and reprogramming: seeing the science through the hype.. Nat Rev Genet. 10(12):878-83.
Nagata S, Toyoda M, Yamaguchi S, Hirano K, Makino H, Nishino K, Miyagawa Y, Okita H, Kiyokawa N, Nakagawa M et al..  2009.  Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells.. Genes Cells. 14(12):1395-404.
Tanaka T, Tohyama S, Murata M, Nomura F, Kaneko T, Chen H, Hattori F, Egashira T, Seki T, Ohno Y et al..  2009.  In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes.. Biochem Biophys Res Commun. 385(4):497-502.
Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S.  2009.  Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.. Nature. 460(7259):1132-5.
Silva J, Nichols J, Theunissen TW, Guo G, van Oosten AL, Barrandon O, Wray J, Yamanaka S, Chambers I, Smith A.  2009.  Nanog is the gateway to the pluripotent ground state.. Cell. 138(4):722-37.
Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M et al..  2009.  Variation in the safety of induced pluripotent stem cell lines.. Nat Biotechnol. 27(8):743-5.
Yamanaka S.  2009.  A fresh look at iPS cells.. Cell. 137(1):13-7.
Takahashi K, Narita M, Yokura M, Ichisaka T, Yamanaka S.  2009.  Human induced pluripotent stem cells on autologous feeders.. PLoS One. 4(12):e8067.
Tanaka Y, Ikeda T, Kishi Y, Masuda S, Shibata H, Takeuchi K, Komura M, Iwanaka T, Muramatsu S-I, Kondo Y et al..  2009.  ERas is expressed in primate embryonic stem cells but not related to tumorigenesis.. Cell Transplant. 18(4):381-9.
Nakamura K, Salomonis N, Tomoda K, Yamanaka S, Conklin BR.  2009.  G(i)-coupled GPCR signaling controls the formation and organization of human pluripotent colonies.. PLoS One. 4(11):e7780.
Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S.  2008.  Generation of mouse induced pluripotent stem cells without viral vectors.. Science. 322(5903):949-53.
Yamanaka S.  2008.  Pluripotency and nuclear reprogramming.. Philos Trans R Soc Lond B Biol Sci. 363(1500):2079-87.
Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK.  2008.  Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells.. Circulation. 118(5):498-506.
Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S.  2008.  Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts.. Nat Biotechnol. 26(1):101-6.
Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S.  2008.  Generation of pluripotent stem cells from adult mouse liver and stomach cells.. Science. 321(5889):699-702.
Hyun I, Hochedlinger K, Jaenisch R, Yamanaka S.  2007.  New advances in iPS cell research do not obviate the need for human embryonic stem cells.. Cell Stem Cell. 1(4):367-8.
Lewitzky M, Yamanaka S.  2007.  Reprogramming somatic cells towards pluripotency by defined factors.. Curr Opin Biotechnol. 18(5):467-73.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S.  2007.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.. Cell. 131(5):861-72.
Okita K, Ichisaka T, Yamanaka S.  2007.  Generation of germline-competent induced pluripotent stem cells.. Nature. 448(7151):313-7.
Takahashi K, Okita K, Nakagawa M, Yamanaka S.  2007.  Induction of pluripotent stem cells from fibroblast cultures.. Nat Protoc. 2(12):3081-9.
Yamanaka S.  2006.  [Molecular mechanisms underlying pluripotency of embryonic stem cells].. Seikagaku. 78(1):27-33.
Okita K, Yamanaka S.  2006.  Intracellular signaling pathways regulating pluripotency of embryonic stem cells.. Curr Stem Cell Res Ther. 1(1):103-11.
Yamanaka S, Takahashi K.  2006.  [Induction of pluripotent stem cells from mouse fibroblast cultures].. Tanpakushitsu Kakusan Koso. 51(15):2346-51.
Tanaka TS, de Silanes ILopez, Sharova LV, Akutsu H, Yoshikawa T, Amano H, Yamanaka S, Gorospe M, Ko MSH.  2006.  Esg1, expressed exclusively in preimplantation embryos, germline, and embryonic stem cells, is a putative RNA-binding protein with broad RNA targets.. Dev Growth Differ. 48(6):381-90.
Tokuzawa Y, Maruyama M, Yamanaka S.  2006.  Utilization of digital differential display to identify novel targets of Oct3/4.. Methods Mol Biol. 329:223-31.
Takahashi K, Ichisaka T, Yamanaka S.  2006.  Identification of genes involved in tumor-like properties of embryonic stem cells.. Methods Mol Biol. 329:449-58.
Amano H, Itakura K, Maruyama M, Ichisaka T, Nakagawa M, Yamanaka S.  2006.  Identification and targeted disruption of the mouse gene encoding ESG1 (PH34/ECAT2/DPPA5).. BMC Dev Biol. 6:11.
Imamura M, Miura K, Iwabuchi K, Ichisaka T, Nakagawa M, Lee J, Kanatsu-Shinohara M, Shinohara T, Yamanaka S.  2006.  Transcriptional repression and DNA hypermethylation of a small set of ES cell marker genes in male germline stem cells.. BMC Dev Biol. 6:34.
Takahashi K, Nakagawa M, Young SG, Yamanaka S.  2005.  Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway.. J Biol Chem. 280(38):32768-74.
Nakagawa M, Yamanaka S.  2005.  [Mechanism for maintaining pluripotency in embryonic stem cells and inner cell mass].. Tanpakushitsu Kakusan Koso. 50(6 Suppl):546-50.
Takahashi K, Maruyama M, Tokuzawa Y, Murakami M, Oda Y, Yoshikane N, Makabe KW, Ichisaka T, Yamanaka S.  2005.  Evolutionarily conserved non-AUG translation initiation in NAT1/p97/DAP5 (EIF4G2).. Genomics. 85(3):360-71.
Maruyama M, Ichisaka T, Nakagawa M, Yamanaka S.  2005.  Differential roles for Sox15 and Sox2 in transcriptional control in mouse embryonic stem cells.. J Biol Chem. 280(26):24371-9.
Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S, Kato J-Y.  2004.  Multiple functions of Jab1 are required for early embryonic development and growth potential in mice.. J Biol Chem. 279(41):43013-8.
Matsuda E, Shigeoka T, Iida R, Yamanaka S, Kawaichi M, Ishida Y.  2004.  Expression profiling with arrays of randomly disrupted genes in mouse embryonic stem cells leads to in vivo functional analysis.. Proc Natl Acad Sci U S A. 101(12):4170-4.
Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S.  2003.  The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells.. Cell. 113(5):631-42.
Takahashi K, Mitsui K, Yamanaka S.  2003.  Role of ERas in promoting tumour-like properties in mouse embryonic stem cells.. Nature. 423(6939):541-5.
Tokuzawa Y, Kaiho E, Maruyama M, Takahashi K, Mitsui K, Maeda M, Niwa H, Yamanaka S.  2003.  Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development.. Mol Cell Biol. 23(8):2699-708.

Araki H, Miura F, Watanabe A, Morinaga C, Kitaoka F, Kitano Y, Sakai N, Shibata Y, Terada M, Goto S, Yamanaka S, Takahashi M, Ito T. Base-Resolution Methylome of Retinal Pigment Epithelial Cells Used in the First Trial of Human Induced Pluripotent Stem Cell-Based Autologous Transplantation. Stem Cell Reports. 2019 Oct 08; 13(4):761-774.

Kime C, Kiyonari H, Ohtsuka S, Kohbayashi E, Asahi M, Yamanaka S, Takahashi M, Tomoda K. Induced 2C Expression and Implantation-Competent Blastocyst-like Cysts from Primed Pluripotent Stem Cells. Stem Cell Reports. 2019 Sep 10; 13(3):485-498.

Suga M, Kondo T, Imamura K, Shibukawa R, Okanishi Y, Sagara Y, Tsukita K, Enami T, Furujo M, Saijo K, Nakamura Y, Osawa M, Saito MK, Yamanaka S, Inoue H. Generation of a human induced pluripotent stem cell line, BRCi001-A, derived from a patient with mucopolysaccharidosis type I. Stem Cell Res. 2019 04; 36:101406.

Karagiannis P, Yamanaka S, Saito MK. Application of induced pluripotent stem cells to primary immunodeficiency diseases. Exp Hematol. 2019 03; 71:43-50.

Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, Inoue H, Yamashita JK, Todani M, Nakagawa M, Osawa M, Yashiro Y, Yamanaka S, Osafune K. Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development. Physiol Rev. 2019 01 01; 99(1):79-114.

Tsuji O, Sugai K, Yamaguchi R, Tashiro S, Nagoshi N, Kohyama J, Iida T, Ohkubo T, Itakura G, Isoda M, Shinozaki M, Fujiyoshi K, Kanemura Y, Yamanaka S, Nakamura M, Okano H. Concise Review: Laying the Groundwork for a First-In-Human Study of an Induced Pluripotent Stem Cell-Based Intervention for Spinal Cord Injury. Stem Cells. 2019 01; 37(1):6-13.

Rand TA, Sutou K, Tanabe K, Jeong D, Nomura M, Kitaoka F, Tomoda E, Narita M, Nakamura M, Nakamura M, Watanabe A, Rulifson E, Yamanaka S, Takahashi K. MYC Releases Early Reprogrammed Human Cells from Proliferation Pause via Retinoblastoma Protein Inhibition. Cell Rep. 2018 Apr 10; 23(2):361-375.

Ikeda H, Sone M, Yamanaka S, Yamamoto T. Structural and spatial chromatin features at developmental gene loci in human pluripotent stem cells. Nat Commun. 2017 11 20; 8(1):1616.

Yagi M, Yamanaka S, Yamada Y. Epigenetic foundations of pluripotent stem cells that recapitulate in vivo pluripotency. Lab Invest. 2017 10; 97(10):1133-1141.

Morizane A, Kikuchi T, Hayashi T, Mizuma H, Takara S, Doi H, Mawatari A, Glasser MF, Shiina T, Ishigaki H, Itoh Y, Okita K, Yamasaki E, Doi D, Onoe H, Ogasawara K, Yamanaka S, Takahashi J. MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun. 2017 08 30; 8(1):385.

Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Funakoshi S, Yoshida Y, Yamanaka S, Shimizu T, Okano T, Daimon T, Toda K, Sawa Y. Enhanced Therapeutic Effects of Human iPS Cell Derived-Cardiomyocyte by Combined Cell-Sheets with Omental Flap Technique in Porcine Ischemic Cardiomyopathy Model. Sci Rep. 2017 08 18; 7(1):8824.

Yoshida Y, Yamanaka S. Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications. Circ Res. 2017 Jun 09; 120(12):1958-1968.

Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, Hotta A, Kondo T, Kitaoka S, Ohta A, Tanaka A, Watanabe D, Morita M, Takuma H, Tamaoka A, Kunath T, Wray S, Furuya H, Era T, Makioka K, Okamoto K, Fujisawa T, Nishitoh H, Homma K, Ichijo H, Julien JP, Obata N, Hosokawa M, Akiyama H, Kaneko S, Ayaki T, Ito H, Kaji R, Takahashi R, Yamanaka S, Inoue H. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017 05 24; 9(391).

Sone M, Morone N, Nakamura T, Tanaka A, Okita K, Woltjen K, Nakagawa M, Heuser JE, Yamada Y, Yamanaka S, Yamamoto T. Hybrid Cellular Metabolism Coordinated by Zic3 and Esrrb Synergistically Enhances Induction of Naive Pluripotency. Cell Metab. 2017 May 02; 25(5):1103-1117.e6.

Karagiannis P, Onodera A, Yamanaka S. New Models for Therapeutic Innovation from Japan. EBioMedicine. 2017 04; 18:3-4.

Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, Fujihara M, Akimaru H, Sakai N, Shibata Y, Terada M, Nomiya Y, Tanishima S, Nakamura M, Kamao H, Sugita S, Onishi A, Ito T, Fujita K, Kawamata S, Go MJ, Shinohara C, Hata KI, Sawada M, Yamamoto M, Ohta S, Ohara Y, Yoshida K, Kuwahara J, Kitano Y, Amano N, Umekage M, Kitaoka F, Tanaka A, Okada C, Takasu N, Ogawa S, Yamanaka S, Takahashi M. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. N Engl J Med. 2017 03 16; 376(11):1038-1046.

Sugiyama H, Takahashi K, Yamamoto T, Iwasaki M, Narita M, Nakamura M, Rand TA, Nakagawa M, Watanabe A, Yamanaka S. Nat1 promotes translation of specific proteins that induce differentiation of mouse embryonic stem cells. Proc Natl Acad Sci U S A. 2017 01 10; 114(2):340-345.

Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017 02; 16(2):115-130.

Hayashi Y, Hsiao EC, Sami S, Lancero M, Schlieve CR, Nguyen T, Yano K, Nagahashi A, Ikeya M, Matsumoto Y, Nishimura K, Fukuda A, Hisatake K, Tomoda K, Asaka I, Toguchida J, Conklin BR, Yamanaka S. BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13057-13062.

Sasaki K, Makiyama T, Yoshida Y, Wuriyanghai Y, Kamakura T, Nishiuchi S, Hayano M, Harita T, Yamamoto Y, Kohjitani H, Hirose S, Chen J, Kawamura M, Ohno S, Itoh H, Takeuchi A, Matsuoka S, Miura M, Sumitomo N, Horie M, Yamanaka S, Kimura T. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia. PLoS One. 2016; 11(10):e0164795.

Kime C, Sakaki-Yumoto M, Goodrich L, Hayashi Y, Sami S, Derynck R, Asahi M, Panning B, Yamanaka S, Tomoda K. Autotaxin-mediated lipid signaling intersects with LIF and BMP signaling to promote the naive pluripotency transcription factor program. Proc Natl Acad Sci U S A. 2016 11 01; 113(44):12478-12483.

Parr CJ, Katayama S, Miki K, Kuang Y, Yoshida Y, Morizane A, Takahashi J, Yamanaka S, Saito H. MicroRNA-302 switch to identify and eliminate undifferentiated human pluripotent stem cells. Sci Rep. 2016 09 09; 6:32532.

Nishizawa M, Chonabayashi K, Nomura M, Tanaka A, Nakamura M, Inagaki A, Nishikawa M, Takei I, Oishi A, Tanabe K, Ohnuki M, Yokota H, Koyanagi-Aoi M, Okita K, Watanabe A, Takaori-Kondo A, Yamanaka S, Yoshida Y. Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. Cell Stem Cell. 2016 09 01; 19(3):341-54.

Ameku T, Taura D, Sone M, Numata T, Nakamura M, Shiota F, Toyoda T, Matsui S, Araoka T, Yasuno T, Mae S, Kobayashi H, Kondo N, Kitaoka F, Amano N, Arai S, Ichisaka T, Matsuura N, Inoue S, Yamamoto T, Takahashi K, Asaka I, Yamada Y, Ubara Y, Muso E, Fukatsu A, Watanabe A, Sato Y, Nakahata T, Mori Y, Koizumi A, Nakao K, Yamanaka S, Osafune K. Identification of MMP1 as a novel risk factor for intracranial aneurysms in ADPKD using iPSC models. Sci Rep. 2016 07 15; 6:30013.

Yamakawa T, Sato Y, Matsumura Y, Kobayashi Y, Kawamura Y, Goshima N, Yamanaka S, Okita K. Screening of Human cDNA Library Reveals Two differentiation-Related Genes, HHEX and HLX, as Promoters of Early Phase Reprogramming toward Pluripotency. Stem Cells. 2016 11; 34(11):2661-2669.

Fukusumi H, Shofuda T, Bamba Y, Yamamoto A, Kanematsu D, Handa Y, Okita K, Nakamura M, Yamanaka S, Okano H, Kanemura Y. Establishment of Human Neural Progenitor Cells from Human Induced Pluripotent Stem Cells with Diverse Tissue Origins. Stem Cells Int. 2016; 2016:7235757.

Nakagawa M, Karagiannis P, Yamanaka S. When Myc's asleep, embryonic stem cells are dormant. EMBO J. 2016 Apr 15; 35(8):801-2.

Myers SA, Peddada S, Chatterjee N, Friedrich T, Tomoda K, Krings G, Thomas S, Maynard J, Broeker M, Thomson M, Pollard K, Yamanaka S, Burlingame AL, Panning B. SOX2 O-GlcNAcylation alters its protein-protein interactions and genomic occupancy to modulate gene expression in pluripotent cells. Elife. 2016 Mar 07; 5:e10647.

Azuma K, Yamanaka S. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies. Regen Ther. 2016 Jun; 4:36-47.

Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol. 2016 Mar; 17(3):183-93.

Funakoshi S, Miki K, Takaki T, Okubo C, Hatani T, Chonabayashi K, Nishikawa M, Takei I, Oishi A, Narita M, Hoshijima M, Kimura T, Yamanaka S, Yoshida Y. Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes. Sci Rep. 2016 Jan 08; 6:19111.

Kime C, Mandegar MA, Srivastava D, Yamanaka S, Conklin BR, Rand TA. Efficient CRISPR/Cas9-Based Genome Engineering in Human Pluripotent Stem Cells. Curr Protoc Hum Genet. 2016 Jan 01; 88:21.4.1-21.4.23.

Kim SI, Oceguera-Yanez F, Sakurai C, Nakagawa M, Yamanaka S, Woltjen K. Inducible Transgene Expression in Human iPS Cells Using Versatile All-in-One piggyBac Transposons. Methods Mol Biol. 2016; 1357:111-31.

Hayakawa T, Aoi T, Umezawa A, Ozawa K, Sato Y, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogeneic human induced pluripotent stem(-Like) cells. Regen Ther. 2015 Dec; 2:95-108.

Hayakawa T, Aoi T, Umezawa A, Ozawa K, Sato Y, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells. Regen Ther. 2015 Dec; 2:57-69.

Hayakawa T, Aoi T, Umezawa A, Ozawa K, Sato Y, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells. Regen Ther. 2015 Dec; 2:81-94.

Kime C, Rand TA, Ivey KN, Srivastava D, Yamanaka S, Tomoda K. Practical Integration-Free Episomal Methods for Generating Human Induced Pluripotent Stem Cells. Curr Protoc Hum Genet. 2015 Oct 06; 87:21.2.1-21.2.21.

Takahashi K, Yamanaka S. A developmental framework for induced pluripotency. Development. 2015 Oct 01; 142(19):3274-85.

Hotta A, Yamanaka S. From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing. Annu Rev Genet. 2015; 49:47-70.

Toyohara T, Mae S, Sueta S, Inoue T, Yamagishi Y, Kawamoto T, Kasahara T, Hoshina A, Toyoda T, Tanaka H, Araoka T, Sato-Otsubo A, Takahashi K, Sato Y, Yamaji N, Ogawa S, Yamanaka S, Osafune K. Cell Therapy Using Human Induced Pluripotent Stem Cell-Derived Renal Progenitors Ameliorates Acute Kidney Injury in Mice. Stem Cells Transl Med. 2015 Sep; 4(9):980-92.

Sasaki K, Yokobayashi S, Nakamura T, Okamoto I, Yabuta Y, Kurimoto K, Ohta H, Moritoki Y, Iwatani C, Tsuchiya H, Nakamura S, Sekiguchi K, Sakuma T, Yamamoto T, Mori T, Woltjen K, Nakagawa M, Yamamoto T, Takahashi K, Yamanaka S, Saitou M. Robust In Vitro Induction of Human Germ Cell Fate from Pluripotent Stem Cells. Cell Stem Cell. 2015 Aug 06; 17(2):178-94.

Miki K, Endo K, Takahashi S, Funakoshi S, Takei I, Katayama S, Toyoda T, Kotaka M, Takaki T, Umeda M, Okubo C, Nishikawa M, Oishi A, Narita M, Miyashita I, Asano K, Hayashi K, Osafune K, Yamanaka S, Saito H, Yoshida Y. Efficient Detection and Purification of Cell Populations Using Synthetic MicroRNA Switches. Cell Stem Cell. 2015 Jun 04; 16(6):699-711.

Sadahiro T, Yamanaka S, Ieda M. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications. Circ Res. 2015 Apr 10; 116(8):1378-91.

Hayashi Y, Caboni L, Das D, Yumoto F, Clayton T, Deller MC, Nguyen P, Farr CL, Chiu HJ, Miller MD, Elsliger MA, Deacon AM, Godzik A, Lesley SA, Tomoda K, Conklin BR, Wilson IA, Yamanaka S, Fletterick RJ. Structure-based discovery of NANOG variant with enhanced properties to promote self-renewal and reprogramming of pluripotent stem cells. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4666-71.

Kim SI, Oceguera-Yanez F, Hirohata R, Linker S, Okita K, Yamada Y, Yamamoto T, Yamanaka S, Woltjen K. KLF4 N-terminal variance modulates induced reprogramming to pluripotency. Stem Cell Reports. 2015 Apr 14; 4(4):727-43.

Wilmut I, Leslie S, Martin NG, Peschanski M, Rao M, Trounson A, Turner D, Turner ML, Yamanaka S, Taylor CJ. Development of a global network of induced pluripotent stem cell haplobanks. Regen Med. 2015; 10(3):235-8.

Tamaoki N, Takahashi K, Aoki H, Iida K, Kawaguchi T, Hatakeyama D, Inden M, Chosa N, Ishisaki A, Kunisada T, Shibata T, Goshima N, Yamanaka S, Tezuka K. The homeobox gene DLX4 promotes generation of human induced pluripotent stem cells. Sci Rep. 2014 Dec 04; 4:7283.

Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H, Yamamoto T, Yamanaka S, Hotta A. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports. 2015 Jan 13; 4(1):143-154.

Tokunaga K, Saitoh N, Goldberg IG, Sakamoto C, Yasuda Y, Yoshida Y, Yamanaka S, Nakao M. Computational image analysis of colony and nuclear morphology to evaluate human induced pluripotent stem cells. Sci Rep. 2014 Nov 11; 4:6996.

Karagiannis P, Yamanaka S. The fate of cell reprogramming. Nat Methods. 2014 Oct; 11(10):1006-8.

Ohnuki M, Tanabe K, Sutou K, Teramoto I, Sawamura Y, Narita M, Nakamura M, Tokunaga Y, Nakamura M, Watanabe A, Yamanaka S, Takahashi K. Dynamic regulation of human endogenous retroviruses mediates factor-induced reprogramming and differentiation potential. Proc Natl Acad Sci U S A. 2014 Aug 26; 111(34):12426-31.

Andrews PW, Cavagnaro J, Cavanagro J, Deans R, Feigal E, Feigel E, Horowitz E, Keating A, Rao M, Turner M, Wilmut I, Yamanaka S. Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nat Biotechnol. 2014 Aug; 32(8):724-6.

Spencer CI, Baba S, Nakamura K, Hua EA, Sears MA, Fu CC, Zhang J, Balijepalli S, Tomoda K, Hayashi Y, Lizarraga P, Wojciak J, Scheinman MM, Aalto-Setälä K, Makielski JC, January CT, Healy KE, Kamp TJ, Yamanaka S, Conklin BR. Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia. Stem Cell Reports. 2014 Aug 12; 3(2):269-81.

Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H, Yamanaka S, Inoue H. Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports. 2014 Aug 12; 3(2):242-9.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Sasaki A, Yamamoto M, Nakamura M, Sutou K, Osafune K, Yamanaka S. Induction of pluripotency in human somatic cells via a transient state resembling primitive streak-like mesendoderm. Nat Commun. 2014 Apr 24; 5:3678.

Numasawa-Kuroiwa Y, Okada Y, Shibata S, Kishi N, Akamatsu W, Shoji M, Nakanishi A, Oyama M, Osaka H, Inoue K, Takahashi K, Yamanaka S, Kosaki K, Takahashi T, Okano H. Involvement of ER stress in dysmyelination of Pelizaeus-Merzbacher Disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes. Stem Cell Reports. 2014 May 06; 2(5):648-61.

Shimamoto R, Amano N, Ichisaka T, Watanabe A, Yamanaka S, Okita K. Generation and characterization of induced pluripotent stem cells from Aid-deficient mice. PLoS One. 2014; 9(4):e94735.

Hirata N, Nakagawa M, Fujibayashi Y, Yamauchi K, Murata A, Minami I, Tomioka M, Kondo T, Kuo TF, Endo H, Inoue H, Sato SI, Ando S, Kawazoe Y, Aiba K, Nagata K, Kawase E, Chang YT, Suemori H, Eto K, Nakauchi H, Yamanaka S, Nakatsuji N, Ueda K, Uesugi M. A chemical probe that labels human pluripotent stem cells. Cell Rep. 2014 Mar 27; 6(6):1165-1174.

Nakamura S, Takayama N, Hirata S, Seo H, Endo H, Ochi K, Fujita K, Koike T, Harimoto K, Dohda T, Watanabe A, Okita K, Takahashi N, Sawaguchi A, Yamanaka S, Nakauchi H, Nishimura S, Eto K. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell. 2014 Apr 03; 14(4):535-48.

Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A, Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T, Soejima H, Moriwaki H, Yamanaka S, Woltjen K, Yamada Y. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell. 2014 Feb 13; 156(4):663-77.

Inoue H, Nagata N, Kurokawa H, Yamanaka S. iPS cells: a game changer for future medicine. EMBO J. 2014 Mar 03; 33(5):409-17.

Nagata N, Yamanaka S. Perspectives for induced pluripotent stem cell technology: new insights into human physiology involved in somatic mosaicism. Circ Res. 2014 Jan 31; 114(3):505-10.

Araoka T, Mae S, Kurose Y, Uesugi M, Ohta A, Yamanaka S, Osafune K. Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule-based differentiation methods. PLoS One. 2014; 9(1):e84881.

Bershteyn M, Hayashi Y, Desachy G, Hsiao EC, Sami S, Tsang KM, Weiss LA, Kriegstein AR, Yamanaka S, Wynshaw-Boris A. Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells. Nature. 2014 Mar 06; 507(7490):99-103.

Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, Morizane A, Doi D, Takahashi J, Nishizawa M, Yoshida Y, Toyoda T, Osafune K, Sekiguchi K, Yamanaka S. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci Rep. 2014 Jan 08; 4:3594.

Tanabe K, Takahashi K, Yamanaka S. Induction of pluripotency by defined factors. Proc Jpn Acad Ser B Phys Biol Sci. 2014; 90(3):83-96.

Matsumoto Y, Hayashi Y, Schlieve CR, Ikeya M, Kim H, Nguyen TD, Sami S, Baba S, Barruet E, Nasu A, Asaka I, Otsuka T, Yamanaka S, Conklin BR, Toguchida J, Hsiao EC. Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J Rare Dis. 2013 Dec 09; 8:190.

Payer B, Rosenberg M, Yamaji M, Yabuta Y, Koyanagi-Aoi M, Hayashi K, Yamanaka S, Saitou M, Lee JT. Tsix RNA and the germline factor, PRDM14, link X reactivation and stem cell reprogramming. Mol Cell. 2013 Dec 26; 52(6):805-18.

Koyanagi-Aoi M, Ohnuki M, Takahashi K, Okita K, Noma H, Sawamura Y, Teramoto I, Narita M, Sato Y, Ichisaka T, Amano N, Watanabe A, Morizane A, Yamada Y, Sato T, Takahashi J, Yamanaka S. Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. Proc Natl Acad Sci U S A. 2013 Dec 17; 110(51):20569-74.

Yamanaka S. The winding road to pluripotency (Nobel Lecture). Angew Chem Int Ed Engl. 2013 Dec 23; 52(52):13900-9.

Worringer KA, Rand TA, Hayashi Y, Sami S, Takahashi K, Tanabe K, Narita M, Srivastava D, Yamanaka S. The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. Cell Stem Cell. 2014 Jan 02; 14(1):40-52.

Ohta S, Nishida E, Yamanaka S, Yamamoto T. Global splicing pattern reversion during somatic cell reprogramming. Cell Rep. 2013 Oct 31; 5(2):357-66.

Turner M, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, Trounson A, Turner D, Yamanaka S, Wilmut I. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell. 2013 Oct 03; 13(4):382-4.

Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, Hayashi T, Onoe H, Shiina T, Yamanaka S, Takahashi J. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports. 2013; 1(4):283-92.

Pandey RR, Tokuzawa Y, Yang Z, Hayashi E, Ichisaka T, Kajita S, Asano Y, Kunieda T, Sachidanandam R, Chuma S, Yamanaka S, Pillai RS. Tudor domain containing 12 (TDRD12) is essential for secondary PIWI interacting RNA biogenesis in mice. Proc Natl Acad Sci U S A. 2013 Oct 08; 110(41):16492-7.

Tanabe K, Nakamura M, Narita M, Takahashi K, Yamanaka S. Maturation, not initiation, is the major roadblock during reprogramming toward pluripotency from human fibroblasts. Proc Natl Acad Sci U S A. 2013 Jul 23; 110(30):12172-9.

Miki K, Yoshida Y, Yamanaka S. Making steady progress on direct cardiac reprogramming toward clinical application. Circ Res. 2013 Jun 21; 113(1):13-5.

Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A, Yoshida M, Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H. Response to comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells". Sci Transl Med. 2013 Jun 05; 5(188):188lr2.

Takahashi K, Yamanaka S. Induced pluripotent stem cells in medicine and biology. Development. 2013 Jun; 140(12):2457-61.

Kaneko S, Yamanaka S. To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell. 2013 Apr 04; 12(4):385-6.

Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, Goshima N, Yamanaka S. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2013 Mar; 31(3):458-66.

Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, Ueno S, Seki T, Kobayashi K, Toda T, Murakami K, Irie K, Klein WL, Mori H, Asada T, Takahashi R, Iwata N, Yamanaka S, Inoue H. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aß and differential drug responsiveness. Cell Stem Cell. 2013 Apr 04; 12(4):487-96.

Kamakura T, Makiyama T, Sasaki K, Yoshida Y, Wuriyanghai Y, Chen J, Hattori T, Ohno S, Kita T, Horie M, Yamanaka S, Kimura T. Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ J. 2013; 77(5):1307-14.

Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, Ikeda E, Yamanaka S, Miura K. Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res. 2013 Feb 01; 112(3):523-33.

Veraitch O, Kobayashi T, Imaizumi Y, Akamatsu W, Sasaki T, Yamanaka S, Amagai M, Okano H, Ohyama M. Human induced pluripotent stem cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vivo. J Invest Dermatol. 2013 Jun; 133(6):1479-88.

Watanabe A, Yamada Y, Yamanaka S. Epigenetic regulation in pluripotent stem cells: a key to breaking the epigenetic barrier. Philos Trans R Soc Lond B Biol Sci. 2013 Jan 05; 368(1609):20120292.

Yamashita A, Liu S, Woltjen K, Thomas B, Meng G, Hotta A, Takahashi K, Ellis J, Yamanaka S, Rancourt DE. Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells. Sci Rep. 2013; 3:1978.

Mae SI, Shono A, Shiota F, Yasuno T, Kajiwara M, Gotoda-Nishimura N, Arai S, Sato-Otubo A, Toyoda T, Takahashi K, Nakayama N, Cowan CA, Aoi T, Ogawa S, McMahon AP, Yamanaka S, Osafune K. Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells. Nat Commun. 2013; 4:1367.

Yamanaka S. Shinya Yamanaka: purveyor of pluripotency. Interview by Ruth Williams. Circ Res. 2013 Jan 18; 112(2):233-5.

Yamana R, Iwasaki M, Wakabayashi M, Nakagawa M, Yamanaka S, Ishihama Y. Rapid and deep profiling of human induced pluripotent stem cell proteome by one-shot NanoLC-MS/MS analysis with meter-scale monolithic silica columns. J Proteome Res. 2013 Jan 04; 12(1):214-21.

Fujishiro SH, Nakano K, Mizukami Y, Azami T, Arai Y, Matsunari H, Ishino R, Nishimura T, Watanabe M, Abe T, Furukawa Y, Umeyama K, Yamanaka S, Ema M, Nagashima H, Hanazono Y. Generation of naive-like porcine-induced pluripotent stem cells capable of contributing to embryonic and fetal development. Stem Cells Dev. 2013 Feb 01; 22(3):473-82.

Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A, Yoshida M, Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med. 2012 Aug 01; 4(145):145ra104.

Kajiwara M, Aoi T, Okita K, Takahashi R, Inoue H, Takayama N, Endo H, Eto K, Toguchida J, Uemoto S, Yamanaka S. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):12538-43.

Tomoda K, Takahashi K, Leung K, Okada A, Narita M, Yamada NA, Eilertson KE, Tsang P, Baba S, White MP, Sami S, Srivastava D, Conklin BR, Panning B, Yamanaka S. Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells. Cell Stem Cell. 2012 Jul 06; 11(1):91-9.

Tanaka T, Takahashi K, Yamane M, Tomida S, Nakamura S, Oshima K, Niwa A, Nishikomori R, Kambe N, Hara H, Mitsuyama M, Morone N, Heuser JE, Yamamoto T, Watanabe A, Sato-Otsubo A, Ogawa S, Asaka I, Heike T, Yamanaka S, Nakahata T, Saito MK. Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. Blood. 2012 Aug 09; 120(6):1299-308.

Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012 Jun 14; 10(6):678-684.

Blanpain C, Daley GQ, Hochedlinger K, Passegué E, Rossant J, Yamanaka S. Stem cells assessed. Nat Rev Mol Cell Biol. 2012 06 08; 13(7):471-6.

Hayashi Y, Saitou M, Yamanaka S. Germline development from human pluripotent stem cells toward disease modeling of infertility. Fertil Steril. 2012 Jun; 97(6):1250-9.

Miki K, Uenaka H, Saito A, Miyagawa S, Sakaguchi T, Higuchi T, Shimizu T, Okano T, Yamanaka S, Sawa Y. Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats. Stem Cells Transl Med. 2012 May; 1(5):430-7.

Sakurai H, Yamanaka S. [Research for cell therapy by induced pluripotent stem cell]. Nihon Rinsho. 2011 Dec; 69(12):2114-8.

Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S, Benvenisty N, Ben-Yosef D, Biancotti JC, Bosman A, Brena RM, Brison D, Caisander G, Camarasa MV, Chen J, Chiao E, Choi YM, Choo AB, Collins D, Colman A, Crook JM, Daley GQ, Dalton A, De Sousa PA, Denning C, Downie J, Dvorak P, Montgomery KD, Feki A, Ford A, Fox V, Fraga AM, Frumkin T, Ge L, Gokhale PJ, Golan-Lev T, Gourabi H, Gropp M, Lu G, Hampl A, Harron K, Healy L, Herath W, Holm F, Hovatta O, Hyllner J, Inamdar MS, Irwanto AK, Ishii T, Jaconi M, Jin Y, Kimber S, Kiselev S, Knowles BB, Kopper O, Kukharenko V, Kuliev A, Lagarkova MA, Laird PW, Lako M, Laslett AL, Lavon N, Lee DR, Lee JE, Li C, Lim LS, Ludwig TE, Ma Y, Maltby E, Mateizel I, Mayshar Y, Mileikovsky M, Minger SL, Miyazaki T, Moon SY, Moore H, Mummery C, Nagy A, Nakatsuji N, Narwani K, Oh SK, Oh SK, Olson C, Otonkoski T, Pan F, Park IH, Pells S, Pera MF, Pereira LV, Qi O, Raj GS, Reubinoff B, Robins A, Robson P, Rossant J, Salekdeh GH, Schulz TC, Sermon K, Sheik Mohamed J, Shen H, Sherrer E, Sidhu K, Sivarajah S, Skottman H, Spits C, Stacey GN, Strehl R, Strelchenko N, Suemori H, Sun B, Suuronen R, Takahashi K, Tuuri T, Venu P, Verlinsky Y, Ward-van Oostwaard D, Weisenberger DJ, Wu Y, Yamanaka S, Young L, Zhou Q. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011 Nov 27; 29(12):1132-44.

Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M, Kerkelä E, Hyttinen J, Kontula K, Swan H, Conklin BR, Yamanaka S, Silvennoinen O, Aalto-Setälä K. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech. 2012 Mar; 5(2):220-30.

Maekawa M, Yamanaka S. Glis1, a unique pro-reprogramming factor, may facilitate clinical applications of iPSC technology. Cell Cycle. 2011 Nov 01; 10(21):3613-4.

Hiratsuka M, Uno N, Ueda K, Kurosaki H, Imaoka N, Kazuki K, Ueno E, Akakura Y, Katoh M, Osaki M, Kazuki Y, Nakagawa M, Yamanaka S, Oshimura M. Integration-free iPS cells engineered using human artificial chromosome vectors. PLoS One. 2011; 6(10):e25961.

Yahata N, Asai M, Kitaoka S, Takahashi K, Asaka I, Hioki H, Kaneko T, Maruyama K, Saido TC, Nakahata T, Asada T, Yamanaka S, Iwata N, Inoue H. Anti-Aß drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One. 2011; 6(9):e25788.

Nori S, Okada Y, Yasuda A, Tsuji O, Takahashi Y, Kobayashi Y, Fujiyoshi K, Koike M, Uchiyama Y, Ikeda E, Toyama Y, Yamanaka S, Nakamura M, Okano H. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci U S A. 2011 Oct 04; 108(40):16825-30.

Okita K, Nagata N, Yamanaka S. Immunogenicity of induced pluripotent stem cells. Circ Res. 2011 Sep 16; 109(7):720-1.

Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet. 2011 Dec 01; 20(23):4530-9.

Nakamura T, Nakagawa M, Ichisaka T, Shiota A, Yamanaka S. Essential roles of ECAT15-2/Dppa2 in functional lung development. Mol Cell Biol. 2011 Nov; 31(21):4366-78.

Wang YC, Nakagawa M, Garitaonandia I, Slavin I, Altun G, Lacharite RM, Nazor KL, Tran HT, Lynch CL, Leonardo TR, Liu Y, Peterson SE, Laurent LC, Yamanaka S, Loring JF. Specific lectin biomarkers for isolation of human pluripotent stem cells identified through array-based glycomic analysis. Cell Res. 2011 Nov; 21(11):1551-63.

Uosaki H, Fukushima H, Takeuchi A, Matsuoka S, Nakatsuji N, Yamanaka S, Yamashita JK. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One. 2011; 6(8):e23657.

Okita K, Yamanaka S. Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci. 2011 Aug 12; 366(1575):2198-207.

Maekawa M, Yamaguchi K, Nakamura T, Shibukawa R, Kodanaka I, Ichisaka T, Kawamura Y, Mochizuki H, Goshima N, Yamanaka S. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature. 2011 Jun 08; 474(7350):225-9.

Higashi H, Brüstle O, Daley GQ, Yamanaka S. The nomenclature system should be sustainable, but also practical. Cell Stem Cell. 2011 Jun 03; 8(6):606-7.

Iwabuchi KA, Yamakawa T, Sato Y, Ichisaka T, Takahashi K, Okita K, Yamanaka S. ECAT11/L1td1 is enriched in ESCs and rapidly activated during iPSC generation, but it is dispensable for the maintenance and induction of pluripotency. PLoS One. 2011; 6(5):e20461.

Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011 May; 8(5):409-12.

Fujiwara M, Yan P, Otsuji TG, Narazaki G, Uosaki H, Fukushima H, Kuwahara K, Harada M, Matsuda H, Matsuoka S, Okita K, Takahashi K, Nakagawa M, Ikeda T, Sakata R, Mummery CL, Nakatsuji N, Yamanaka S, Nakao K, Yamashita JK. Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. PLoS One. 2011 Feb 22; 6(2):e16734.

Yamanaka S. Genome-sequencing anniversary. Of mice and humans. Science. 2011 Feb 18; 331(6019):873.

Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohyama M, Amagai M, Matsuzaki Y, Yamanaka S, Okano H, Kawakami Y. Generation of human melanocytes from induced pluripotent stem cells. PLoS One. 2011 Jan 13; 6(1):e16182.

Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, Endo H, Yamaguchi T, Otsu M, Nishimura K, Nakanishi M, Sawaguchi A, Nagai R, Takahashi K, Yamanaka S, Nakauchi H, Eto K. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med. 2010 Dec 20; 207(13):2817-30.

Nakahata T, Awaya T, Chang H, Mizuno Y, Niwa A, Fukada S, Takeda S, Yamanaka S, Heike T. [Derivation of engraftable myogenic precursors from murine ES/iPS cells and generation of disease-specific iPS cells from patients with Duchenne muscular dystrophy (DMD) and other diseases]. Rinsho Shinkeigaku. 2010 Nov; 50(11):889.

Yoshida Y, Yamanaka S. iPS cells: a source of cardiac regeneration. J Mol Cell Cardiol. 2011 Feb; 50(2):327-32.

Egusa H, Okita K, Kayashima H, Yu G, Fukuyasu S, Saeki M, Matsumoto T, Yamanaka S, Yatani H. Gingival fibroblasts as a promising source of induced pluripotent stem cells. PLoS One. 2010 Sep 14; 5(9):e12743.

Imamura M, Aoi T, Tokumasu A, Mise N, Abe K, Yamanaka S, Noce T. Induction of primordial germ cells from mouse induced pluripotent stem cells derived from adult hepatocytes. Mol Reprod Dev. 2010 Sep; 77(9):802-11.

Espejel S, Roll GR, McLaughlin KJ, Lee AY, Zhang JY, Laird DJ, Okita K, Yamanaka S, Willenbring H. Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest. 2010 Sep; 120(9):3120-6.

Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14152-7.

Yoshida Y, Yamanaka S. Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell-based regeneration. Circulation. 2010 Jul 06; 122(1):80-7.

Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S, Higashi H, Nagai T, Katoh H, Kohda K, Matsuzaki Y, Yuzaki M, Ikeda E, Toyama Y, Nakamura M, Yamanaka S, Okano H. Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12704-9.

Yamanaka S. Patient-specific pluripotent stem cells become even more accessible. Cell Stem Cell. 2010 Jul 02; 7(1):1-2.

Saunders LR, Sharma AD, Tawney J, Nakagawa M, Okita K, Yamanaka S, Willenbring H, Verdin E. miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY). 2010 Jul; 2(7):415-31.

Kaichi S, Hasegawa K, Takaya T, Yokoo N, Mima T, Kawamura T, Morimoto T, Ono K, Baba S, Doi H, Yamanaka S, Nakahata T, Heike T. Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc Res. 2010 Nov 01; 88(2):314-23.

Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. Nature. 2010 Jun 10; 465(7299):704-12.

Sato S, Yagi S, Arai Y, Hirabayashi K, Hattori N, Iwatani M, Okita K, Ohgane J, Tanaka S, Wakayama T, Yamanaka S, Shiota K. Genome-wide DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) residing in mouse pluripotent stem cells. Genes Cells. 2010 Jun; 15(6):607-18.

Yamanaka S. An interview with... Shinya Yamanaka. Interview by Mary Muers. Nat Rev Genet. 2010 Jun; 11(6):390.

Okita K, Yamanaka S. Induction of pluripotency by defined factors. Exp Cell Res. 2010 Oct 01; 316(16):2565-70.

Homma K, Sone M, Taura D, Yamahara K, Suzuki Y, Takahashi K, Sonoyama T, Inuzuka M, Fukunaga Y, Tamura N, Itoh H, Yamanaka S, Nakao K. Sirt1 plays an important role in mediating greater functionality of human ES/iPS-derived vascular endothelial cells. Atherosclerosis. 2010 Sep; 212(1):42-7.

Mizuno Y, Chang H, Umeda K, Niwa A, Iwasa T, Awaya T, Fukada S, Yamamoto H, Yamanaka S, Nakahata T, Heike T. Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells. FASEB J. 2010 Jul; 24(7):2245-53.

Okita K, Hong H, Takahashi K, Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc. 2010 Mar; 5(3):418-28.

Nakagawa M, Yamanaka S. Reprogramming of somatic cells to pluripotency. Adv Exp Med Biol. 2010; 695:215-24.

Kazuki Y, Hiratsuka M, Takiguchi M, Osaki M, Kajitani N, Hoshiya H, Hiramatsu K, Yoshino T, Kazuki K, Ishihara C, Takehara S, Higaki K, Nakagawa M, Takahashi K, Yamanaka S, Oshimura M. Complete genetic correction of ips cells from Duchenne muscular dystrophy. Mol Ther. 2010 Feb; 18(2):386-93.

Takahashi K, Narita M, Yokura M, Ichisaka T, Yamanaka S. Human induced pluripotent stem cells on autologous feeders. PLoS One. 2009 Dec 02; 4(12):e8067.

Nagata S, Toyoda M, Yamaguchi S, Hirano K, Makino H, Nishino K, Miyagawa Y, Okita H, Kiyokawa N, Nakagawa M, Yamanaka S, Akutsu H, Umezawa A, Tada T. Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells. Genes Cells. 2009 Dec; 14(12):1395-404.

Nakamura K, Salomonis N, Tomoda K, Yamanaka S, Conklin BR. G(i)-coupled GPCR signaling controls the formation and organization of human pluripotent colonies. PLoS One. 2009 Nov 10; 4(11):e7780.

Niwa A, Umeda K, Chang H, Saito M, Okita K, Takahashi K, Nakagawa M, Yamanaka S, Nakahata T, Heike T. Orderly hematopoietic development of induced pluripotent stem cells via Flk-1(+) hemoangiogenic progenitors. J Cell Physiol. 2009 Nov; 221(2):367-77.

Izpisúa Belmonte JC, Ellis J, Hochedlinger K, Yamanaka S. Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Nat Rev Genet. 2009 12; 10(12):878-83.

Yamanaka S. Ekiden to iPS Cells. Nat Med. 2009 Oct; 15(10):1145-8.

Nishimura K, Nakagawa T, Ono K, Ogita H, Sakamoto T, Yamamoto N, Okita K, Yamanaka S, Ito J. Transplantation of mouse induced pluripotent stem cells into the cochlea. Neuroreport. 2009 Sep 23; 20(14):1250-4.

Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell. 2009 Sep 04; 5(3):237-41.

Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009 Aug 27; 460(7259):1132-5.

Yokoo N, Baba S, Kaichi S, Niwa A, Mima T, Doi H, Yamanaka S, Nakahata T, Heike T. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun. 2009 Sep 25; 387(3):482-8.

Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol. 2009 Aug; 27(8):743-5.

Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature. 2009 Jul 02; 460(7251):49-52.

Ohnuki M, Takahashi K, Yamanaka S. Generation and characterization of human induced pluripotent stem cells. Curr Protoc Stem Cell Biol. 2009 Jun; Chapter 4:Unit 4A.2.

Tanaka T, Tohyama S, Murata M, Nomura F, Kaneko T, Chen H, Hattori F, Egashira T, Seki T, Ohno Y, Koshimizu U, Yuasa S, Ogawa S, Yamanaka S, Yasuda K, Fukuda K. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun. 2009 Aug 07; 385(4):497-502.

Tsubooka N, Ichisaka T, Okita K, Takahashi K, Nakagawa M, Yamanaka S. Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts. Genes Cells. 2009 Jun; 14(6):683-94.

Taura D, Sone M, Homma K, Oyamada N, Takahashi K, Tamura N, Yamanaka S, Nakao K. Induction and isolation of vascular cells from human induced pluripotent stem cells--brief report. Arterioscler Thromb Vasc Biol. 2009 Jul; 29(7):1100-3.

Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K, Okita K, Yamanaka S, Nishimura Y. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells. 2009 May; 27(5):1021-31.

Hirami Y, Osakada F, Takahashi K, Okita K, Yamanaka S, Ikeda H, Yoshimura N, Takahashi M. Generation of retinal cells from mouse and human induced pluripotent stem cells. Neurosci Lett. 2009 Jul 24; 458(3):126-31.

Yamanaka S. A fresh look at iPS cells. Cell. 2009 Apr 03; 137(1):13-7.

Daley GQ, Lensch MW, Jaenisch R, Meissner A, Plath K, Yamanaka S. Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell. 2009 Mar 06; 4(3):200-1; author reply 202.

Taura D, Noguchi M, Sone M, Hosoda K, Mori E, Okada Y, Takahashi K, Homma K, Oyamada N, Inuzuka M, Sonoyama T, Ebihara K, Tamura N, Itoh H, Suemori H, Nakatsuji N, Okano H, Yamanaka S, Nakao K. Adipogenic differentiation of human induced pluripotent stem cells: comparison with that of human embryonic stem cells. FEBS Lett. 2009 Mar 18; 583(6):1029-33.

Tanaka Y, Ikeda T, Kishi Y, Masuda S, Shibata H, Takeuchi K, Komura M, Iwanaka T, Muramatsu S, Kondo Y, Takahashi K, Yamanaka S, Hanazono Y. ERas is expressed in primate embryonic stem cells but not related to tumorigenesis. Cell Transplant. 2009; 18(4):381-9.

Aiba K, Nedorezov T, Piao Y, Nishiyama A, Matoba R, Sharova LV, Sharov AA, Yamanaka S, Niwa H, Ko MS. Defining developmental potency and cell lineage trajectories by expression profiling of differentiating mouse embryonic stem cells. DNA Res. 2009 Feb; 16(1):73-80.

Aoyama Y, Nomura M, Yamanaka S, Ogawa Y, Kitajima Y. Subcutaneous phaeohyphomycosis caused by Exophiala xenobiotica in a non-Hodgkin lymphoma patient. Med Mycol. 2009 Feb; 47(1):95-9.

Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008 Nov 07; 322(5903):949-53.

Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008 Jul 29; 118(5):498-506.

Yamanaka S. Pluripotency and nuclear reprogramming. Philos Trans R Soc Lond B Biol Sci. 2008 Jun 27; 363(1500):2079-87.

Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science. 2008 Aug 01; 321(5889):699-702.

Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008 Jan; 26(1):101-6.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 Nov 30; 131(5):861-72.

Hyun I, Hochedlinger K, Jaenisch R, Yamanaka S. New advances in iPS cell research do not obviate the need for human embryonic stem cells. Cell Stem Cell. 2007 Oct 11; 1(4):367-8.

Lewitzky M, Yamanaka S. Reprogramming somatic cells towards pluripotency by defined factors. Curr Opin Biotechnol. 2007 Oct; 18(5):467-73.

Yoshikane N, Nakamura N, Ueda R, Ueno N, Yamanaka S, Nakamura M. Drosophila NAT1, a homolog of the vertebrate translational regulator NAT1/DAP5/p97, is required for embryonic germband extension and metamorphosis. Dev Growth Differ. 2007 Sep; 49(7):623-34.

Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell. 2007 Jun 07; 1(1):39-49.

Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007 Jul 19; 448(7151):313-7.

Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc. 2007; 2(12):3081-9.

Yamanaka S, Takahashi K. [Induction of pluripotent stem cells from mouse fibroblast cultures]. Tanpakushitsu Kakusan Koso. 2006 Dec; 51(15):2346-51.

Nimura K, Ishida C, Koriyama H, Hata K, Yamanaka S, Li E, Ura K, Kaneda Y. Dnmt3a2 targets endogenous Dnmt3L to ES cell chromatin and induces regional DNA methylation. Genes Cells. 2006 Oct; 11(10):1225-37.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25; 126(4):663-76.

Tanaka TS, Lopez de Silanes I, Sharova LV, Akutsu H, Yoshikawa T, Amano H, Yamanaka S, Gorospe M, Ko MS. Esg1, expressed exclusively in preimplantation embryos, germline, and embryonic stem cells, is a putative RNA-binding protein with broad RNA targets. Dev Growth Differ. 2006 Aug; 48(6):381-90.

Imamura M, Miura K, Iwabuchi K, Ichisaka T, Nakagawa M, Lee J, Kanatsu-Shinohara M, Shinohara T, Yamanaka S. Transcriptional repression and DNA hypermethylation of a small set of ES cell marker genes in male germline stem cells. BMC Dev Biol. 2006 Jul 21; 6:34.

Amano H, Itakura K, Maruyama M, Ichisaka T, Nakagawa M, Yamanaka S. Identification and targeted disruption of the mouse gene encoding ESG1 (PH34/ECAT2/DPPA5). BMC Dev Biol. 2006 Feb 28; 6:11.

Takahashi K, Ichisaka T, Yamanaka S. Identification of genes involved in tumor-like properties of embryonic stem cells. Methods Mol Biol. 2006; 329:449-58.

Okita K, Yamanaka S. Intracellular signaling pathways regulating pluripotency of embryonic stem cells. Curr Stem Cell Res Ther. 2006 Jan; 1(1):103-11.

Tokuzawa Y, Maruyama M, Yamanaka S. Utilization of digital differential display to identify novel targets of Oct3/4. Methods Mol Biol. 2006; 329:223-31.

Yamanaka S. [Molecular mechanisms underlying pluripotency of embryonic stem cells]. Seikagaku. 2006 Jan; 78(1):27-33.

Takahashi K, Nakagawa M, Young SG, Yamanaka S. Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J Biol Chem. 2005 Sep 23; 280(38):32768-74.

Ishiyama K, Takami A, Okumura H, Ozaki J, Shimadoi S, Yamanaka S, Nakao S. Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy. Int J Hematol. 2005 May; 81(4):319-22.

Nakagawa M, Yamanaka S. [Mechanism for maintaining pluripotency in embryonic stem cells and inner cell mass]. Tanpakushitsu Kakusan Koso. 2005 May; 50(6 Suppl):546-50.

Maruyama M, Ichisaka T, Nakagawa M, Yamanaka S. Differential roles for Sox15 and Sox2 in transcriptional control in mouse embryonic stem cells. J Biol Chem. 2005 Jul 01; 280(26):24371-9.

Takahashi K, Maruyama M, Tokuzawa Y, Murakami M, Oda Y, Yoshikane N, Makabe KW, Ichisaka T, Yamanaka S. Evolutionarily conserved non-AUG translation initiation in NAT1/p97/DAP5 (EIF4G2). Genomics. 2005 Mar; 85(3):360-71.

Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S, Kato JY. Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J Biol Chem. 2004 Oct 08; 279(41):43013-8.

Matsuda E, Shigeoka T, Iida R, Yamanaka S, Kawaichi M, Ishida Y. Expression profiling with arrays of randomly disrupted genes in mouse embryonic stem cells leads to in vivo functional analysis. Proc Natl Acad Sci U S A. 2004 Mar 23; 101(12):4170-4.

Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003 May 30; 113(5):631-42.

Takahashi K, Mitsui K, Yamanaka S. Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. Nature. 2003 May 29; 423(6939):541-5.

Tokuzawa Y, Kaiho E, Maruyama M, Takahashi K, Mitsui K, Maeda M, Niwa H, Yamanaka S. Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development. Mol Cell Biol. 2003 Apr; 23(8):2699-708.

Qian X, Balestra ME, Yamanaka S, Borén J, Lee I, Innerarity TL. Low expression of the apolipoprotein B mRNA-editing transgene in mice reduces LDL levels but does not cause liver dysplasia or tumors. Arterioscler Thromb Vasc Biol. 1998 Jun; 18(6):1013-20.

Yamanaka S, Poksay KS, Arnold KS, Innerarity TL. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Genes Dev. 1997 Feb 01; 11(3):321-33.

Yamanaka S, Poksay KS, Driscoll DM, Innerarity TL. Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif. J Biol Chem. 1996 May 10; 271(19):11506-10.

Yamanaka S, Poksay KS, Balestra ME, Zeng GQ, Innerarity TL. Cloning and mutagenesis of the rabbit ApoB mRNA editing protein. A zinc motif is essential for catalytic activity, and noncatalytic auxiliary factor(s) of the editing complex are widely distributed. J Biol Chem. 1994 Aug 26; 269(34):21725-34.